We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.94%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$76.2B
AUM Growth
+$2.6B
(+3.5%)
Cap. Flow
-$2.97B
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
21.61%
Holding
3,238
New
235
Increased
684
Reduced
2,065
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$77.3M |
| 2 |
Blackstone
BX
|
+$53.2M |
| 3 |
NXP Semiconductors
NXPI
|
+$40.8M |
| 4 |
Palantir
PLTR
|
+$34.3M |
| 5 |
Snowflake
SNOW
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$206M |
| 2 |
Microsoft
MSFT
|
+$163M |
| 3 |
Linde
LIN
|
+$133M |
| 4 |
Amazon
AMZN
|
+$94.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$82.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.34% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.06% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Arcus Biosciences
RCUS
$3.64B
| $1.8M | ﹤0.01% |
65,528
+17,755
| +37% | +$507K |
|
2002
MannKind Corp
MNKD
$1.32B
| $1.79M | ﹤0.01% |
328,907
+96,631
| +42% | +$419K |
|
2003
Cass Information Systems
CASS
$743M
| $1.79M | ﹤0.01% |
43,908
+2,298
| +6% | +$103K |
|
|
CNST
2004
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $1.79M | ﹤0.01% |
52,829
+17,435
| +49% | +$444K |
|
2005
Stride
LRN
$3.43B
| $1.78M | ﹤0.01% |
55,399
-7,000
| -11% | -$209K |
|
2006
Enterprise Financial Services Corp
EFSC
$2.39B
| $1.77M | ﹤0.01% |
38,138
+311
| +0.8% | +$15.2K |
|
2007
iShares S&P 500 Value ETF
IVE
$49.8B
| $1.76M | ﹤0.01% |
11,958
| – | – |
|
|
PR
2008
Permian Resources
PR
$16.9B
| $1.76M | ﹤0.01% |
260,131
+231,675
| +814% | +$1.2M |
|
2009
Atea Pharmaceuticals
AVIR
$420M
| $1.76M | ﹤0.01% |
82,096
+64,933
| +378% | +$1.95M |
|
2010
Hyliion Holdings
HYLN
$690M
| $1.76M | ﹤0.01% |
+151,126
| New | +$1.58M |
|
|
IMGN
2011
DELISTED
Immunogen Inc
IMGN
| $1.76M | ﹤0.01% |
267,019
-15,673
| -6% | -$109K |
|
|
BFS
2012
Saul Centers
BFS
$834M
| $1.76M | ﹤0.01% |
38,665
-1,626
| -4% | -$70.6K |
|
2013
OceanFirst Financial
OCFC
$1.91B
| $1.75M | ﹤0.01% |
84,058
-9,256
| -10% | -$207K |
|
2014
German American Bancorp
GABC
$1.9B
| $1.75M | ﹤0.01% |
46,989
-3,976
| -8% | -$167K |
|
2015
Kearny Financial
KRNY
$599M
| $1.75M | ﹤0.01% |
146,227
-12,758
| -8% | -$161K |
|
2016
Tootsie Roll Industries
TR
$2.98B
| $1.74M | ﹤0.01% |
59,459
+3,832
| +7% | +$108K |
|
2017
Talos Energy
TALO
$2.4B
| $1.73M | ﹤0.01% |
110,395
+22,893
| +26% | +$316K |
|
2018
Bally's
BALY
$658M
| $1.72M | ﹤0.01% |
31,705
+12,258
| +63% | +$691K |
|
2019
PDF Solutions
PDFS
$2.07B
| $1.71M | ﹤0.01% |
94,259
+8,015
| +9% | +$144K |
|
2020
Oil States International
OIS
$491M
| $1.7M | ﹤0.01% |
216,718
-12,241
| -5% | -$82K |
|
2021
Zentalis Pharmaceuticals
ZNTL
$300M
| $1.7M | ﹤0.01% |
31,890
+1,281
| +4% | +$68.6K |
|
2022
Playtika
PLTK
$1.12B
| $1.69M | ﹤0.01% |
70,938
+2,607
| +4% | +$68.2K |
|
|
SPPI
2023
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $1.69M | ﹤0.01% |
450,550
-53,369
| -11% | -$185K |
|
2024
TriCo Bancshares
TCBK
$1.83B
| $1.67M | ﹤0.01% |
39,222
-3,681
| -9% | -$171K |
|
|
SUMO
2025
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $1.67M | ﹤0.01% |
80,805
+64,113
| +384% | +$1.24M |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, RhumbLine Advisers held 3,238 positions worth $76.2B, up 3.5% from $73.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers withdrew a net $2.97B in Q2 2021, closing 243 positions and reducing 2,065 holdings. Its most notable exit was Varian Medical Systems, Inc., an estimated $32.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in DraftKings worth $14.2M.
- RhumbLine Advisers's largest Q2 2021 buy was DraftKings: 271,227 shares worth $14.2M.
- RhumbLine Advisers added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $77.3M increase.
- RhumbLine Advisers's biggest Q2 2021 reduction was Apple, cutting an estimated $206M.
- RhumbLine Advisers fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $32.1M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $76.2B portfolio in Q2 2021.
- RhumbLine Advisers opened 235 new positions and closed 243 in Q2 2021.
- RhumbLine Advisers's portfolio value rose 3.5% quarter-over-quarter to $76.2B.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.